Procter & Gamble Health Limited (PGHL.NS)
INR 5230.5
(1.22%)
INR 5230.5
(1.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.78 Billion INR | -11.34% |
| 2022 | 3.14 Billion INR | 20.72% |
| 2021 | 2.6 Billion INR | 10.78% |
| 2020 | 2.34 Billion INR | 19.38% |
| 2019 | 1.96 Billion INR | 14.95% |
| 2018 | 1.71 Billion INR | -11.01% |
| 2017 | 1.92 Billion INR | 47.69% |
| 2016 | 1.3 Billion INR | 99.53% |
| 2015 | 653 Million INR | 39.26% |
| 2014 | 468.9 Million INR | -32.26% |
| 2013 | 692.2 Million INR | -41.68% |
| 2012 | 1.18 Billion INR | 24.15% |
| 2011 | 956.1 Million INR | -13.13% |
| 2010 | 1.1 Billion INR | 14.08% |
| 2009 | 964.8 Million INR | 5.16% |
| 2008 | 917.5 Million INR | -8.13% |
| 2007 | 998.7 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion INR | 163.49% |
| 2023 Q3 | 631.9 Million INR | -33.29% |
| 2023 FY | 2.78 Billion INR | -11.34% |
| 2023 Q2 | 947.3 Million INR | 7.37% |
| 2023 Q1 | 882.3 Million INR | 99.71% |
| 2023 Q4 | 410.9 Million INR | -34.97% |
| 2022 Q1 | 867.6 Million INR | 41.88% |
| 2022 Q2 | 1.06 Billion INR | 22.97% |
| 2022 Q3 | 766.1 Million INR | -28.19% |
| 2022 Q4 | 441.8 Million INR | -42.33% |
| 2022 FY | 3.14 Billion INR | 20.72% |
| 2021 Q1 | 742.1 Million INR | 69.82% |
| 2021 Q3 | 650 Million INR | 8.42% |
| 2021 Q4 | 611.5 Million INR | -5.92% |
| 2021 Q2 | 599.5 Million INR | -19.22% |
| 2021 FY | 2.6 Billion INR | 10.78% |
| 2020 Q3 | 263 Million INR | -69.64% |
| 2020 Q2 | 866.2 Million INR | 11.83% |
| 2020 FY | 2.34 Billion INR | 19.38% |
| 2020 Q1 | 774.6 Million INR | 71.97% |
| 2020 Q4 | 437 Million INR | 66.16% |
| 2019 Q4 | 450.44 Million INR | -17.35% |
| 2019 FY | 1.96 Billion INR | 14.95% |
| 2019 Q3 | 545.01 Million INR | 21.82% |
| 2019 Q2 | 447.39 Million INR | -2.43% |
| 2019 Q1 | 458.51 Million INR | -8.34% |
| 2018 Q4 | 500.22 Million INR | 9.21% |
| 2018 Q2 | 107.15 Million INR | -80.11% |
| 2018 Q1 | 538.74 Million INR | 21.32% |
| 2018 FY | 1.71 Billion INR | -11.01% |
| 2018 Q3 | 458.03 Million INR | 327.47% |
| 2017 Q3 | 385.82 Million INR | -6.19% |
| 2017 FY | 1.92 Billion INR | 47.69% |
| 2017 Q4 | 444.08 Million INR | 15.1% |
| 2017 Q2 | 411.28 Million INR | -17.72% |
| 2017 Q1 | 499.88 Million INR | 135.46% |
| 2016 Q3 | 230.7 Million INR | -22.25% |
| 2016 Q4 | 212.3 Million INR | -7.98% |
| 2016 FY | 1.3 Billion INR | 99.53% |
| 2016 Q1 | 429.94 Million INR | 59.73% |
| 2016 Q2 | 296.73 Million INR | -30.98% |
| 2015 Q2 | 234.35 Million INR | 16.14% |
| 2015 FY | 653 Million INR | 39.26% |
| 2015 Q4 | 269.17 Million INR | 64.21% |
| 2015 Q3 | 163.91 Million INR | -30.06% |
| 2015 Q1 | 201.79 Million INR | -23.17% |
| 2014 Q4 | 262.66 Million INR | 95.33% |
| 2014 FY | 468.9 Million INR | -32.26% |
| 2014 Q1 | 265.36 Million INR | -16.11% |
| 2014 Q2 | -172.98 Million INR | -165.19% |
| 2014 Q3 | 134.47 Million INR | 177.74% |
| 2013 Q4 | 316.31 Million INR | 425.45% |
| 2013 FY | 692.2 Million INR | -41.68% |
| 2013 Q2 | -13.21 Million INR | -105.41% |
| 2013 Q1 | 244.46 Million INR | -4.16% |
| 2013 Q3 | 60.2 Million INR | 555.51% |
| 2012 Q4 | 255.06 Million INR | 23.89% |
| 2012 Q3 | 205.88 Million INR | -53.81% |
| 2012 FY | 1.18 Billion INR | 24.15% |
| 2012 Q2 | 445.74 Million INR | 32.26% |
| 2012 Q1 | 337.03 Million INR | 10.46% |
| 2011 Q4 | 305.1 Million INR | 64.63% |
| 2011 Q1 | 261.96 Million INR | 0.0% |
| 2011 Q2 | 425.9 Million INR | 62.58% |
| 2011 Q3 | 185.32 Million INR | -56.49% |
| 2011 FY | 956.1 Million INR | -13.13% |
| 2010 FY | 1.1 Billion INR | 14.08% |
| 2009 FY | 964.8 Million INR | 5.16% |
| 2008 FY | 917.5 Million INR | -8.13% |
| 2007 FY | 998.7 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Hester Biosciences Limited | 364.77 Million INR | -663.769% |
| RPG Life Sciences Limited | 2.29 Billion INR | -21.537% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 39.535% |
| Ipca Laboratories Limited | 29.59 Billion INR | 90.587% |
| Aarti Drugs Limited | 7.14 Billion INR | 61.028% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 10.937% |
| Albert David Limited | 1.33 Billion INR | -108.774% |
| Alembic Limited | 767.77 Million INR | -262.869% |
| Alkem Laboratories Limited | 19.46 Billion INR | 85.685% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 51.616% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -1072.258% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -13387.607% |
| Brooks Laboratories Limited | -72.25 Million INR | 3955.949% |
| Eris Lifesciences Limited | 5.18 Billion INR | 46.234% |
| FDC Limited | 3.03 Billion INR | 8.166% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 68.973% |
| Gufic Biosciences Limited | 2.89 Billion INR | 3.725% |
| Hikal Limited | 1.49 Billion INR | -86.454% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -38.674% |
| Ind-Swift Limited | 1.22 Billion INR | -127.25% |
| Innova Captab Limited | 2.53 Billion INR | -9.97% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 43.628% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -1201.626% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 46.31% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1239.101% |
| Laurus Labs Limited | 3.94 Billion INR | 29.443% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -46.145% |
| Lupin Limited | 27.75 Billion INR | 89.963% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -10046.405% |
| Medico Remedies Limited | 277.11 Million INR | -905.348% |
| Morepen Laboratories Limited | 4.17 Billion INR | 33.251% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 28.391% |
| Orchid Pharma Limited | 2.36 Billion INR | -17.997% |
| Sigachi Industries Limited | 1.47 Billion INR | -89.023% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 172.309% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 97.329% |
| Themis Medicare Limited | 1.3 Billion INR | -113.797% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -44164.379% |
| Venus Remedies Limited | 534.65 Million INR | -421.088% |
| Wanbury Limited | 1.7 Billion INR | -63.191% |
| Windlas Biotech Limited | 1.29 Billion INR | -114.491% |
| ZIM Laboratories Limited | 1.09 Billion INR | -153.708% |
| Sakar Healthcare Limited | 495.5 Million INR | -462.254% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 97.334% |
| Divi's Laboratories Limited | 18.31 Billion INR | 84.784% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 37.728% |
| Mankind Pharma Limited | 40.86 Billion INR | 93.183% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 5.31 Billion INR | 47.613% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 63.058% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 57.154% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 93.862% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -348.612% |
| Wockhardt Limited | 140 Million INR | -1890.0% |
| Bal Pharma Limited | 214.56 Million INR | -1198.417% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 95.887% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -126.32% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -405.086% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 61.441% |
| Shilpa Medicare Limited | 3.76 Billion INR | 25.935% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 85.842% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -98316.505% |
| Granules India Limited | 6.52 Billion INR | 57.324% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1017.749% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 89.003% |
| NATCO Pharma Limited | 25.96 Billion INR | 89.269% |
| Suven Life Sciences Limited | -1.22 Billion INR | 327.276% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 46.688% |
| Indoco Remedies Limited | 1.52 Billion INR | -82.76% |
| Alpa Laboratories Limited | 61.51 Million INR | -4428.977% |
| Lasa Supergenerics Limited | -458 Million INR | 708.29% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 167.703% |